Novel therapeutics to prevent and treat life-threatening viral infections
Chimerix (NASDAQ: CMRX) is an anti-viral drug discovery and development company leveraging a proprietary lipid-conjugate technology to enhance oral absorption and improve antiviral potency. The company's lead product is brincidofovir, an oral broad-spectrum antiviral with potent activity against DNA viruses. Brincidofovir is being developed to prevent and treat infections in a number of patient populations, including prevention of cytomegalovirus in transplant settings and treatment of adenovirus. Chimerix completed its IPO on NASDAQ in 2013.